ACE Inhibitors

1. Front Matter

   Pages I-X

   PDF

2. The history of inhibitors of angiotensin converting enzyme

   • John R. Vane

   Pages 1-10

3. Genetics of the renin-angiotensin-aldosterone system and risk of arterial disease

   • Malika Lajemi, Athanase Benetos

   Pages 11-27

4. Crosstalk between ACE inhibitors, B2 kinin receptor and nitric oxide in endothelial cells

   • Paulus Wohlfart, Gabriele Wiemer, Wolfgang Linz, Bernward A. Schölkens

   Pages 29-36

5. Interactions between the ACE and the endothelin pathway

   • Rob L. Hopfner, J. Robert McNeill, Venkat Gopalakrishnan

   Pages 37-45

6. Evaluative and epidemiological approaches of ACE therapy

   • Maxime Lamarre-Cliche, Pierre Larochelle

   Pages 47-70

7. The role of ACE inhibition in heart failure

   • Irene Gavras, Haralambos Gavras

   Pages 71-79

8. Angiotensin converting enzyme inhibition in the microcirculation

   • Gérard E. Plante, Tewfik Nawar

   Pages 81-103

9. Arterial structure and function and blockade of the renin-angiotensin system in hypertension

   • Michel E. Safar, Harry A. J. Struijker Boudier, Luc M. A. B. Van Bortel, Gérard M. London

   Pages 105-127

10. The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and des-Arg⁹-bradykinin) and effect of ACE inhibitors on their in vitro and in vivo metabolism

    • Albert Adam, Charles Blais Jr., François Marceau

    Pages 129-144

11. Role of the renin-angiotensin system on the central and peripheral autonomic nervous system

    • Jacques de Champlain, Pedro D’Orléans-Juste

    Pages 145-153

12. Dual inhibitors of angiotensin converting enzyme and neutral endopeptidase

    • Cynthia A. Fink

    Pages 155-162

13. Pharmacodynamics, tissue-specificity of ACE inhibitors

    • Stylianos E. Orfanos, Linhua Zou, John D. Catravas

    Pages 163-170

14. Effect of angiotensin converting enzyme inhibition on thirst and salt-appetite

    • Tewfik Nawar, Eve-Reine Gagné, Raymonde Turcotte, Gérard E. Plante

    Pages 171-176

15. ACE and diabetes

    • Mark E. Cooper

    Pages 177-184

16. Back Matter

    Pages 185-187

    PDF

Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis­ order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun­ tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop­ ment almost failed when serious side-effects were reported in an alarmist fash­ ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar­ macological actions.

• diseases
• enzymes
• genetics
• health policy
• heart
• metabolism
• nervous system
• pharmacodynamics
• research
• therapy
• tissue

• Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical School, Sherbrooke University, Sherbrooke, Canada

  Pedro D’Orléans-Juste, Gérard E. Plante

• Departments of Medicine (Nephrology), Physiology and Pharmacology, Institute of Pharmacology, University of Sherbrooke, Sherbrooke, Canada

  Gérard E. Plante

Policies and ethics